Entera Bio (ENTX) Other financing activities (2023 - 2026)

Entera Bio (ENTX) has reported Other financing activities for 4 consecutive years, with $130000.0 the latest figure, recorded in Q1 2026.

• Quarterly Other financing activities fell 13.33% year-over-year to $130000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $488000.0 (down 39.68% YoY) and the FY2025 annual result came in at $508000.0, down 32.18% from the prior year.
• Other financing activities retreated to $130000.0 in Q1 2026 per ENTX's latest filing, from $154000.0 in the prior quarter.
• Over the last five years, Other financing activities for ENTX reached as high as $6.6 million in Q4 2023 and fell as low as $13000.0 in Q3 2024.
• A 4-year average of $793800.0 and a median of $140000.0 in 2025 frame the typical range for Other financing activities.
• Annual changes were most pronounced in 2024 — Other financing activities plunged 98.62% — and 2025, when it jumped 1284.62%.
• Year by year, Other financing activities stood at $6.6 million in 2023, then tumbled by 98.62% to $91000.0 in 2024, then jumped by 69.23% to $154000.0 in 2025, then slipped by 15.58% to $130000.0 in 2026.
• According to Business Quant data, Other financing activities over the past three periods registered $130000.0, $154000.0, and $180000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.